1. Home
  2. DSGN vs PWOD Comparison

DSGN vs PWOD Comparison

Compare DSGN & PWOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • PWOD
  • Stock Information
  • Founded
  • DSGN 2017
  • PWOD 1934
  • Country
  • DSGN United States
  • PWOD United States
  • Employees
  • DSGN N/A
  • PWOD N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • PWOD Major Banks
  • Sector
  • DSGN Health Care
  • PWOD Finance
  • Exchange
  • DSGN Nasdaq
  • PWOD Nasdaq
  • Market Cap
  • DSGN 208.9M
  • PWOD 231.2M
  • IPO Year
  • DSGN 2021
  • PWOD N/A
  • Fundamental
  • Price
  • DSGN $3.87
  • PWOD N/A
  • Analyst Decision
  • DSGN Hold
  • PWOD
  • Analyst Count
  • DSGN 1
  • PWOD 0
  • Target Price
  • DSGN $4.00
  • PWOD N/A
  • AVG Volume (30 Days)
  • DSGN 92.9K
  • PWOD 78.2K
  • Earning Date
  • DSGN 08-12-2025
  • PWOD 08-08-2025
  • Dividend Yield
  • DSGN N/A
  • PWOD 4.27%
  • EPS Growth
  • DSGN N/A
  • PWOD 28.19
  • EPS
  • DSGN N/A
  • PWOD 2.80
  • Revenue
  • DSGN N/A
  • PWOD $74,314,000.00
  • Revenue This Year
  • DSGN N/A
  • PWOD N/A
  • Revenue Next Year
  • DSGN N/A
  • PWOD N/A
  • P/E Ratio
  • DSGN N/A
  • PWOD $10.73
  • Revenue Growth
  • DSGN N/A
  • PWOD 16.68
  • 52 Week Low
  • DSGN $2.60
  • PWOD $20.18
  • 52 Week High
  • DSGN $7.77
  • PWOD $34.56
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 47.12
  • PWOD 5.25
  • Support Level
  • DSGN $3.89
  • PWOD $29.91
  • Resistance Level
  • DSGN $4.19
  • PWOD $32.20
  • Average True Range (ATR)
  • DSGN 0.23
  • PWOD 0.53
  • MACD
  • DSGN -0.02
  • PWOD -3.32
  • Stochastic Oscillator
  • DSGN 16.18
  • PWOD 0.00

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About PWOD Penns Woods Bancorp Inc.

Penns Woods Bancorp Inc is the bank holding company for Jersey Shore State Bank and Luzerne Bank. The banks serve customers in North Central and North Eastern Pennsylvania through their retail banking, commercial banking, mortgage services and financial services divisions. The Banks are engaged in commercial and retail banking which includes the acceptance of time, savings, and demand deposits, the funding of commercial, consumer, and mortgage loans, and safe deposit services. Utilizing a branch office network, ATMs, Internet, and telephone banking delivery channels, the Banks deliver their products and services to the communities residing in.

Share on Social Networks: